ArticleFrontiers in psychiatry2025
Research on comorbidity characteristics and patterns of hospitalized participants with schizophrenia in China.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Participants with schizophrenia face the dual impacts of mental illness and physical diseases, which significantly affect their clinical prognosis and quality of life. Methods: This study, which is based on multivariate clinical data, using data-driven approaches (statistical analysis and data mining techniques) to systematically characterize the comorbidities landscape of schizophrenia patients identifying key patterns and clinical profiles to inform optimized treatment strategies and health management interventions. Results: It was found that the comorbidity rate among hospitalized schizophrenia participants is notably high in China. Notably, significant variations in comorbidity profiles were identified across diverse demographic and clinical variables, including age, occupational status, marital status, duration of hospital stay, frequency of hospitalizations, and health insurance status. The comorbidities in schizophrenia participants primarily include acute upper respiratory infections (J00-J06), metabolic disorders (E70-E90), hypertension (I10-I15), and diabetes (E1 0-E14). Furthermore, four strongly associated comorbidities patterns were identified: the metabolic-cardiovascular comorbidities cluster, the co-disease cluster of respiratory system infection, gut respiratory symptom cluster, electrolyte imbalance infection trigger cluster were identified. Discussion: The exploration of comorbidity characteristics and patterns in schizophrenia provides a quantifiable tool for enhancing treatment and health management outcomes for participants while also offering a reference for advancing the application of precision medicine in the treatment and management of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.